key: cord-0068843-vlfl7bz4
authors: nan
title: Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
date: 2021-10-23
journal: Reactions Weekly
DOI: 10.1007/s40278-021-03978-1
sha: 7f66287253f4ef4144e32f5f68fb410692c7a193
doc_id: 68843
cord_uid: vlfl7bz4

nan

The second study 2 assessed myocarditis within 21 days after dose 1 or 30 days after dose 2 using adapted Brighton Collaboration criteria. The 5442 696 patients vaccinated between 20 December 2020 and 31 May 2021 were identified from the Ministry of Health database. Myocarditis was assessed as definite or probable in 136 patients, comprising 118 males and 18 females. Myocarditis was mild in 129 cases (95%), and resolved in most cases. However, one patient developed fulminant myocarditis and died.

The overall risk difference per 100 000 persons between the first and second doses was 1.76: 3.19 for males and 0.39 for females. The highest difference was in males 16-19 years of age (13.73), with "the first week after the second vaccine dose as the main risk window", note the authors.

The standardised incidence ratio after dose 2 compared to the expected incidence was 5.34. The ratio was higher in males than females for most age groups: 13.60 vs 6.74 for 16-19 years, 8.53 vs 10.76 for 20-24 years, 6.96 vs 2.54 for 25-29 years, and 2.90 vs 2.44 for ≥30 years.

Compared with unvaccinated persons, the myocarditis rate ratio for vaccinated persons was 2.35, and was mostly highest for males: 8.96 vs 2.95 for 16-19 years of age, 6.13 vs 7.56 for 20-24 years, 3.58 vs 0 for 25-29 years, and 1.00 vs 0.82 for ≥30 years.

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Adis © 2021 Springer Nature Switzerland AG. All rights reserved